Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pia Osterlund

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
BJC Reports|October 21, 2025
KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohortsEmerik Osterlund, Ari Ristimäki, Luís Nunes, et al.
The Lancet Regional Health. Europe|September 24, 2021
Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention studyPia Osterlund, Tapio Salminen, Leena-Maija Soveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2014
Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapyGilles Manceau, Sandrine Imbeaud, Raphaële Thiébaut, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
BJC Reports|October 21, 2025
KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohortsEmerik Osterlund, Ari Ristimäki, Luís Nunes, et al.
The Lancet Regional Health. Europe|September 24, 2021
Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention studyPia Osterlund, Tapio Salminen, Leena-Maija Soveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2014
Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapyGilles Manceau, Sandrine Imbeaud, Raphaële Thiébaut, et al.
Pageof 5